Login / Signup

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply.

Adriaan VolkersTessa StraatmijerMarjolijn DuijvesteinMark LöwenbergAndrea van der MeulenGeert D'Haens
Published in: Alimentary pharmacology & therapeutics (2023)
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • peritoneal dialysis
  • prognostic factors
  • high dose
  • patient reported outcomes
  • low dose